The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars

Authors:

Abstract
A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, but most countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF inhibitor biosimilars (infliximab and etanercept).
Funding Information
  • P. Carl Petersens Fond (18071)

This publication has 6 references indexed in Scilit: